Apex Physics Partners, the largest outsourced medical physics services company in North America, announced Wednesday a new partnership with INphysics, Indiana’s market leader for therapy medical physics and dosimetry services. INphysics will complement Apex’s existing diagnostic medical physics footprint, having partnered with Advanced Medical Physics and its leader Will Breeden earlier this year. Based in Indianapolis, INphysics is a multidisciplinary consulting firm offering radiation therapy medical physics and dosimetry services to leading hospital systems and cancer centers throughout Indiana and the United States.

Mesa Laboratories, Inc. (NASDAQ:MLAB) (“we”, “us”, “our”, “Mesa” or the “Company”), a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, announced today that it has entered into a definitive agreement to acquire Agena Bioscience, Inc. (“Agena”) for a cash purchase price of $300 million, subject to customary purchase price adjustments. Agena is headquartered in San Diego, California and is a leading molecular diagnostics tools company that develops, manufactures, and supplies highly sensitive, low-cost, high-throughput, genetic analysis solutions to clinical labs and development partners globally.

Heska Corporation (NASDAQ: HSKA – News; “Heska” or the “Company”), a leading global provider of advanced veterinary diagnostic and specialty products, announced today that the Company has acquired majority ownership of Biotech Laboratories U.S.A. LLC (“Biotech”), an leading developer of rapid assay diagnostics testing, from Biotech Holdings U.S.A. LLC (“Acquisition”). Founded in 2016 and headquartered in Rockville, Maryland, Biotech develops a full line of rapid point-of-care tests to detect antigens and antibodies associated with infectious and parasitic diseases of animals.

Biomeme, the leading provider of portable PCR testing solutions, has signed a definitive agreement to acquire Predigen, a privately held diagnostic company and emerging leader in precision medicine focused on host response diagnostics. Predigen’s acquisition will expand Biomeme’s capabilities across infectious disease and clinical microbiology, business management, and commercialization.

LumiraDx, a next-generation point of care diagnostics testing company, and CA Healthcare Acquisition Corp (Nasdaq: CAHC), a special purpose acquisition company focused on investing in a growth-oriented healthcare company, announced they have revised the valuation of their previously announced transaction based on various considerations. The new transaction terms adjust the pro forma enterprise value of LumiraDx (including CAHC) from $5 billion to $3 billion excluding any cash held in trust by CAHC.